$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| DIRECTOR/PDMR SHAREHOLDING | 13 Nov 2024 |
| DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | 12 Nov 2024 |
| ASTRAZENECA INVESTS $3.5 BILLION IN US | 12 Nov 2024 |
| 9M AND Q3 2024 RESULTS | 12 Nov 2024 |
| KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | 12 Nov 2024 |
| TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | 08 Nov 2024 |
| TOTAL VOTING RIGHTS | 01 Nov 2024 |
| AZN CHINA PRESIDENT UNDER INVESTIGATION | 30 Oct 2024 |
| SC 13G | 28 Oct 2024 |
| FORM 6-K | 21 Oct 2024 |
| SC 13G | 11 Oct 2024 |
| ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | 07 Oct 2024 |
| TOTAL VOTING RIGHTS | 01 Oct 2024 |
| TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | 26 Sep 2024 |
| FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | 23 Sep 2024 |
| FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | 23 Sep 2024 |
| FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | 20 Sep 2024 |
| FASENRA EGPA US FDA APPROVAL | 18 Sep 2024 |
| DIRECTOR/PDMR SHAREHOLDING | 13 Sep 2024 |
| TOTAL VOTING RIGHTS | 03 Sep 2024 |
